• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于胰腺癌患者治疗监测的游离DNA全基因组分析。

Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer.

作者信息

Hruban Carolyn, Bruhm Daniel C, Chen Inna M, Koul Shashikant, Annapragada Akshaya V, Vulpescu Nicholas A, Short Sarah, Theile Susann, Boyapati Kavya, Alipanahi Bahar, Skidmore Zachary L, Leal Alessandro, Cristiano Stephen, Adleff Vilmos, Johannsen Julia S, Scharpf Robert B, Foda Zachariah H, Phallen Jillian, Velculescu Victor E

机构信息

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.

出版信息

Sci Adv. 2025 May 23;11(21):eads5002. doi: 10.1126/sciadv.ads5002. Epub 2025 May 21.

DOI:10.1126/sciadv.ads5002
PMID:40397745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12094228/
Abstract

Determining response to therapy for patients with pancreatic cancer can be challenging. We evaluated methods for assessing therapeutic response using cell-free DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the CheckPAC trial (NCT02866383). Patients were evaluated before and after initiation of therapy using tumor-informed plasma whole-genome sequencing (WGMAF) and tumor-independent genome-wide cfDNA fragmentation profiles and repeat landscapes (ARTEMIS-DELFI). Using WGMAF, molecular responders had a median overall survival (OS) of 319 days compared to 126 days for nonresponders [hazard ratio (HR) = 0.29, 95% confidence interval (CI) = 0.11-0.79,  = 0.011]. For ARTEMIS-DELFI, patients with low scores after therapy initiation had longer median OS than patients with high scores (233 versus 172 days, HR = 0.12, 95% CI = 0.046-0.31,  < 0.0001). We validated ARTEMIS-DELFI in patients with pancreatic cancer in the PACTO trial (NCT02767557). These analyses suggest that noninvasive mutation and fragmentation-based cfDNA approaches can identify therapeutic response of individuals with pancreatic cancer.

摘要

确定胰腺癌患者的治疗反应可能具有挑战性。在CheckPAC试验（NCT02866383）中，我们评估了使用转移性胰腺癌患者血浆中的游离DNA（cfDNA）来评估治疗反应的方法。在治疗开始前后，使用肿瘤知情的血浆全基因组测序（WGMAF）以及与肿瘤无关的全基因组cfDNA片段化图谱和重复序列景观（ARTEMIS-DELFI）对患者进行评估。使用WGMAF，分子反应者的中位总生存期（OS）为319天，而无反应者为126天[风险比（HR）=0.29，95%置信区间（CI）=0.11-0.79，P=0.011]。对于ARTEMIS-DELFI，治疗开始后得分低的患者的中位OS比得分高的患者更长（233天对172天，HR=0.12，95%CI=0.046-0.31，P<0.0001）。我们在PACTO试验（NCT02767557）中的胰腺癌患者中验证了ARTEMIS-DELFI。这些分析表明，基于cfDNA的非侵入性突变和片段化方法可以识别胰腺癌个体的治疗反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/ca696a04521c/sciadv.ads5002-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/1b5a6f58715f/sciadv.ads5002-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/a1f3bf1ae037/sciadv.ads5002-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/44941e93086c/sciadv.ads5002-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/9b1f36cbfb10/sciadv.ads5002-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/4ad9884dee07/sciadv.ads5002-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/7db766a04379/sciadv.ads5002-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/7774cd8ece94/sciadv.ads5002-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/f94174a3a4c3/sciadv.ads5002-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/ca696a04521c/sciadv.ads5002-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/1b5a6f58715f/sciadv.ads5002-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/a1f3bf1ae037/sciadv.ads5002-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/44941e93086c/sciadv.ads5002-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/9b1f36cbfb10/sciadv.ads5002-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/4ad9884dee07/sciadv.ads5002-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/7db766a04379/sciadv.ads5002-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/7774cd8ece94/sciadv.ads5002-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/f94174a3a4c3/sciadv.ads5002-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28f8/12094228/ca696a04521c/sciadv.ads5002-f9.jpg

相似文献

1
Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer.用于胰腺癌患者治疗监测的游离DNA全基因组分析。
Sci Adv. 2025 May 23;11(21):eads5002. doi: 10.1126/sciadv.ads5002. Epub 2025 May 21.
2
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
3
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.无细胞游离 DNA 在转移性结直肠癌中的应用：系统评价和荟萃分析。
Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4.
4
Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation.基于游离DNA甲基化的肝细胞癌无创预后评估
PLoS One. 2025 Apr 25;20(4):e0321736. doi: 10.1371/journal.pone.0321736. eCollection 2025.
5
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.维生素 D 受体基因作为胰腺癌患者生存的决定因素：基因组分析和实验验证。
PLoS One. 2018 Aug 14;13(8):e0202272. doi: 10.1371/journal.pone.0202272. eCollection 2018.
6
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer.用于胰腺癌检测和预后预测的游离DNA检测
Nat Commun. 2025 Jul 18;16(1):6645. doi: 10.1038/s41467-025-61890-z.
7
Chemotherapy and radiotherapy for advanced pancreatic cancer.晚期胰腺癌的化疗与放疗
Cochrane Database Syst Rev. 2024 Dec 5;12(12):CD011044. doi: 10.1002/14651858.CD011044.pub3.
8
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类：一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer.浆细胞游离DNA的基因组和表观基因组分析确定了与致命性前列腺癌生存预后较差相关的干性特征。
Clin Cancer Res. 2025 Jan 6;31(1):151-163. doi: 10.1158/1078-0432.CCR-24-1658.

本文引用的文献

1
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.纳布紫杉醇和吉西他滨联合或不联合托珠单抗作为晚期胰腺癌一线治疗的随机II期研究：生存与恶病质
J Clin Oncol. 2025 Jun 20;43(18):2107-2118. doi: 10.1200/JCO.23.01965. Epub 2025 May 12.
2
Cancer treatment monitoring using cell-free DNA fragmentomes.基于游离 DNA 片段组学的癌症治疗监测。
Nat Commun. 2024 Oct 21;15(1):8801. doi: 10.1038/s41467-024-53017-7.
3
Genome-wide repeat landscapes in cancer and cell-free DNA.
癌症和游离 DNA 中的全基因组重复景观。
Sci Transl Med. 2024 Mar 13;16(738):eadj9283. doi: 10.1126/scitranslmed.adj9283.
4
COSMIC: a curated database of somatic variants and clinical data for cancer.COSMIC：一个针对癌症体细胞变异和临床数据的精选数据库。
Nucleic Acids Res. 2024 Jan 5;52(D1):D1210-D1217. doi: 10.1093/nar/gkad986.
5
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.系统治疗下循环肿瘤 DNA 超低频全基因组测序对肝细胞癌的预后价值。
Clin Mol Hepatol. 2024 Apr;30(2):177-190. doi: 10.3350/cmh.2023.0426. Epub 2023 Dec 29.
6
Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.血浆YKL-40与接受免疫检查点抑制剂联合放疗的转移性胰腺癌患者的预后相关。
Front Immunol. 2023 Sep 7;14:1228907. doi: 10.3389/fimmu.2023.1228907. eCollection 2023.
7
Cell-free DNA approaches for cancer early detection and interception.无细胞游离 DNA 方法在癌症早期检测和干预中的应用。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2022-006013.
8
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.在 POLARIS-03 试验中，整合纵向循环肿瘤 DNA 分析可预测转移性尿路上皮癌的免疫治疗反应。
J Pathol. 2023 Oct;261(2):198-209. doi: 10.1002/path.6166. Epub 2023 Aug 16.
9
Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer.基于游离 DNA 的单分子全基因组突变谱进行癌症的非侵入性检测。
Nat Genet. 2023 Aug;55(8):1301-1310. doi: 10.1038/s41588-023-01446-3. Epub 2023 Jul 27.
10
Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.基于纵向数据和游离DNA特征的新型高精度肝细胞癌预测模型。
J Hepatol. 2023 Oct;79(4):933-944. doi: 10.1016/j.jhep.2023.05.039. Epub 2023 Jun 10.